InhaleRx Ltd
- Country
- Ownership
- -
- Employees
- -
- Market Cap
- -
- Introduction
InhaleRx Ltd focuses on medical inhalation devices for the delivery of prescribed medicines. The Medihale Inhaler utilizes heat (not burn) technology, avoiding the production of pyrolytic toxins and carcinogenic often created when combusting plant material such as tobacco or cannabis leaves of flowers. The sealed tamper-proof Medihale Pods provide patients with the additional security that the Medical Cannabis c-liquid is of good quality.
InhaleRx Secures $38.5 Million Funding to Advance Novel Inhaled Therapies for Cancer Pain and Panic Disorder
• InhaleRx has secured a $38.5 million funding agreement with Clendon Biotech Capital to advance its inhaled medications through clinical trials without shareholder dilution.
• The company has completed its first drawdown of $247,500, which will fund batch manufacturing and stability testing for IRX-211, a non-opioid treatment for Breakthrough Cancer Pain.
• Clinical development will focus on two key products: IRX-211 for cancer pain and IRX-616a for panic disorder, with first patient dosing for IRX-211 expected in Q3 2025.
GH Research's Inhaled Psychedelic GH001 Achieves Significant Results in Phase IIb Trial for Treatment-Resistant Depression
• GH Research's GH001, an inhaled 5-MeO-DMT, met its primary endpoint in a Phase IIb trial for treatment-resistant depression, showing a significant reduction in MADRS scores.
• The trial demonstrated ultra-rapid responses, with substantial reductions in MADRS scores observed as early as two hours post-treatment with GH001.
• GH001 led to a high remission rate at six months in the open-label extension portion of the trial, indicating a sustained therapeutic effect.
• The company reported no serious adverse events, suggesting a favorable safety profile for GH001 in treating TRD.
© Copyright 2025. All Rights Reserved by MedPath